Presentation is loading. Please wait.

Presentation is loading. Please wait.

Aclinical Utility of measuring [IFX] & HACA in Pts with IBD Afif w, et al. Am J Gastroenterol. 2010;105:1133-1139.

Similar presentations


Presentation on theme: "Aclinical Utility of measuring [IFX] & HACA in Pts with IBD Afif w, et al. Am J Gastroenterol. 2010;105:1133-1139."— Presentation transcript:

1 Aclinical Utility of measuring [IFX] & HACA in Pts with IBD Afif w, et al. Am J Gastroenterol. 2010;105:1133-1139

2 Results for IBD Pt with IFX Loss of Response HACA (+) Therapeutic [IFX] > 12 mcg/ml @ 4wk SubTherapeutic [IFX] < 12 mcg/ml @ 4wk ∆ Anti-TNFα ↑ IFX dose or Freq ∆ Anti-TNFα Inactive IBD Endo/Rad 62% of pts Active IBD Endo/Rad 38% Investigate alternative etiology Response rate 92% Failure, ∆ Rx different mechanism Response rate 17 % ↑ IFX dose or FreqResponse rate 86 % Response rate 33 % P R McNally, DO, FACP, FACG

3 Algorithm for IBD Pt with IFX Loss of Response HACA (+) Therapeutic [IFX] > 12 mcg/ml @ 4wk SubTherapeutic [IFX] < 12 mcg/ml @ 4wk ∆ Anti-TNFα ↑ IFX dose or Freq ∆ Anti-TNFα Inactive IBD Endo/Rad Active IBD Endo/Rad ∆ Anti-TNFα Investigate alternative etiology Failure, ∆ Rx different mechanism P R McNally, DO, FACP, FACG


Download ppt "Aclinical Utility of measuring [IFX] & HACA in Pts with IBD Afif w, et al. Am J Gastroenterol. 2010;105:1133-1139."

Similar presentations


Ads by Google